Genmab A/S Release: Daratumumab Data to be Presented at American Society of Clinical Oncology Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark; May 16, 2013 – Genmab A/S (OMX: GEN) announced today that the latest data from the ongoing Phase I/II study of daratumumab in relapsed/refractory multiple myeloma will be presented in an oral session in the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4. Daratumumab is being developed under a collaboration with Janssen Biotech, Inc. and was recently granted Breakthrough Therapy Designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD. Data from two other Genmab programs will also be presented. Abstracts have been published at the ASCO website at http://abstracts2.asco.org/.
Help employers find you! Check out all the jobs and post your resume.
Copenhagen, Denmark; May 16, 2013 – Genmab A/S (OMX: GEN) announced today that the latest data from the ongoing Phase I/II study of daratumumab in relapsed/refractory multiple myeloma will be presented in an oral session in the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4. Daratumumab is being developed under a collaboration with Janssen Biotech, Inc. and was recently granted Breakthrough Therapy Designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD. Data from two other Genmab programs will also be presented. Abstracts have been published at the ASCO website at http://abstracts2.asco.org/.
Help employers find you! Check out all the jobs and post your resume.